Will 2018 Be the Year of CRISPR?

Model of crystal structure for CRISPR-Cas9
Wednesday, December 27, 2017

An article in MIT Technology Review notes, "In just the past few years, advances in [the gene-editing technology] CRISPR have been happening at a breakneck speed — and companies have sprung up to commercialize the technology. Now, patients in Europe and the U.S. could be treated with CRISPR-based therapies as soon as 2018." Looking at actual research, however, the picture is more mixed: trials are planned at Stanford University, for example, but have already been delayed at the University of Pennsylvania. Alexey Bersenev, director of the Advanced Cell Therapy Lab at Yale New Haven Hospital, cautions “the field is currently over-optimistic about possible results of clinical trials. . . . Every new and hot biomedical technology usually undergoes an inflated expectations phase.”